Insmed Incorporated (INSM) Shareholder/Analyst Call Transcript [Seeking Alpha]
Insmed Incorporated (INSM)
Last insmed incorporated earnings: 4/30 07:30 am
Check Earnings Report
US:NASDAQ Investor Relations:
investor.insmed.com
Company Research
Source: Seeking Alpha
Bryan Dunn - Vice President of Investor Relations William Lewis - President, CEO & Chairman Martina Flammer - Chief Medical Officer Sara Bonstein - Chief Financial Officer Kevin Mange - Chief Development Officer Conference Call Participants Graig Suvannavejh - Mizuho Securities USA LLC, Research Division Jason Zemansky - BofA Securities, Research Division Ritu Baral - TD Cowen, Research Division Joseph Schwartz - Leerink Partners LLC, Research Division Vamil Divan - Guggenheim Securities, LLC, Research Division Eliana Merle - Barclays Bank PLC, Research Division Maxwell Skor - Morgan Stanley, Research Division Matthew Phipps - William Blair & Company L.L.C., Research Division Ashwani Verma - UBS Investment Bank, Research Division Leonid Timashev - RBC Capital Markets, Research Division Faisal Khurshid - Jefferies LLC, Research Division Presentation Operator Thank you for standing by, and welcome to the Insmed's Phase IIIb ENCORE study of ARIKAYCE
Show less
Read more
Impact Snapshot
Event Time:
INSM
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
INSM alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
INSM alerts
High impacting Insmed Incorporated news events
Weekly update
A roundup of the hottest topics
INSM
News
- Insmed ENCORE Phase 3 Trial Hits Primary Endpoint; ARIKAYCE Drives Strong MAC Culture Conversion Gains [Yahoo! Finance]Yahoo! Finance
- Insmed shares rise on positive late-stage trial results for lung disease therapy [Yahoo! Finance]Yahoo! Finance
- Insmed (INSM) had its price target lowered by Wells Fargo & Company from $208.00 to $175.00. They now have an "overweight" rating on the stock.MarketBeat
- S&P 500 Futures Rise in Premarket Trading; Insmed, Mobileye Global Lead [Barron's]Barrons
- Insmed Announces Positive Topline Results from Phase 3b ENCORE Study of ARIKAYCE® (Amikacin Liposome Inhalation Suspension) in Patients with MAC Lung Disease [Yahoo! Finance]Yahoo! Finance
INSM
Earnings
- 2/19/26 - Miss
INSM
Sec Filings
- 3/23/26 - Form 8-K
- 3/20/26 - Form 4
- 3/19/26 - Form 144
- INSM's page on the SEC website